Alleviation of preeclampsia-like symptoms through PlGF and eNOS regulation by hypoxia- and NF-κB-responsive miR-214-3p deletion
Experimental & Molecular Medicine · 03.06.2024 · 56 (6) · 1388-1400
DOI: 10.1038/s12276-024-01237-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental & Molecular Medicine, online erschienen am 03.06.2024. Verfasst von Suji Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, 24341, Republic of Korea. Hauptthemen laut MEDLINE: Pre-Eclampsia, MicroRNAs, NF-kappa B, Nitric Oxide Synthase Type III. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Preeclampsia is caused by placental hypoxia and systemic inflammation and is associated with reduced placental growth factor (PlGF) and endothelial nitric oxide synthase (eNOS) levels. The molecular signaling axes involved in this process may play a role in the pathogenesis of preeclampsia. Here, we found that hypoxic exposure increased hypoxia-inducible factor-1α (HIF-1α)/Twist1-mediated miR-214-3p biogenesis in trophoblasts, suppressing PlGF production and trophoblast invasion. TNF-α stimulation increased NF-κB-dependent miR-214-3p expression in endothelial cells, impairing eNOS expression and causing endothelial dysfunction. Synthetic miR-214-3p administration to pregnant mice decreased PlGF and eNOS expression, resulting in preeclampsia-like symptoms, including hypertension, proteinuria, and fetal growth restriction. Conversely, miR-214-3p deletion maintained the PlGF and eNOS levels in hypoxic pregnant mice, alleviating preeclampsia-like symptoms and signs. These findings provide new insights into the role of HIF-1/Twist1- and NF-κB-responsive miR-214-3p-dependent PlGF and eNOS downregulation in the pathogenesis of preeclampsia and establish miR-214-3p as a therapeutic or preventive target for preeclampsia and its complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, 24341, Republic of Korea.
- Department of Biochemistry, Chungbuk National University, Cheongju, 28644, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, 04763, Republic of Korea.
- Department of Biological Sciences, Kangwon National University, Chuncheon, 24341, Republic of Korea.
- Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon, 24341, Republic of Korea.
- Advanced Institute of Technology, Curacle Co. Ltd, Seoul, 06694, Republic of Korea.
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Kim, S., Shim, S., Kwon, J., Ryoo, S., Byeon, J., Hong, J., Lee, J. H., Kwon, Y. G., Kim, J. Y., & Kim, Y. M. (2024). Alleviation of preeclampsia-like symptoms through PlGF and eNOS regulation by hypoxia- and NF-κB-responsive miR-214-3p deletion. Experimental & Molecular Medicine, 56(6), 1388-1400. https://doi.org/10.1038/s12276-024-01237-8
Vancouver
Kim S, Shim S, Kwon J, Ryoo S, Byeon J, Hong J, et al. Alleviation of preeclampsia-like symptoms through PlGF and eNOS regulation by hypoxia- and NF-κB-responsive miR-214-3p deletion. Experimental & Molecular Medicine. 2024;56(6):1388-1400. doi:10.1038/s12276-024-01237-8
BibTeX
@article{Kim2024,
author = {Kim, Suji and Shim, Sungbo and Kwon, Jisoo and Ryoo, Sungwoo and Byeon, Junyoung and Hong, Jungwoo and Lee, Jeong-Hyung and Kwon, Young-Guen and Kim, Ji-Yoon and Kim, Young-Myeong},
title = {Alleviation of preeclampsia-like symptoms through PlGF and eNOS regulation by hypoxia- and NF-κB-responsive miR-214-3p deletion},
journal = {Experimental & Molecular Medicine},
year = {2024},
volume = {56},
number = {6},
pages = {1388--1400},
doi = {10.1038/s12276-024-01237-8}
}
EUVIMED